WASHINGTON — The White House on Wednesday provided the clearest evidence yet that, eventually, some drug makers might not have to cut Medicaid the best deal on prescription drugs.
It would be a big win for drug makers, who say the current rules — which require every drug company to give Medicaid programs the lowest possible price, or “best price,” for any drug they sell — don’t give them the flexibility to test new payment ideas, like paying for drugs based on how well they work.
The planned change to Medicaid’s drug rebate rules, along with a planned rule on high-cost biologic drugs, were both tucked into a list of upcoming potential regulations that the White House releases biannually. Together the rules provide one of the first glimpses of what the administration is likely to pursue next year as part of its plan to lower drug prices.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
